CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study

Ann Oncol 2017; 28: x7 (doi: 10.1093/annonc/mdx729) In the abstract LBA5, the names of authors A. Bertolini and Y. Rukazenkov were originally misspelt. They have now been corrected. Analysis of EGFR mutation status in blood and CSF in lung adenocarcinoma patients with EGFR mutation and CNS metastasis by ddPCRAnnals of OncologyVol. 28PreviewBackground: Patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations benefit a great deal from EGFR tyrosine kinase inhibitors(TKIs). However, most patients recrudesce within one or two years, and many of them progress in the central nerve system (CNS). Owing to the blood–brain barrier, detecting tumor-derived cell-free DNA (cfDNA) in the blood of brain metastasis tumor patients is challenging. Detecting tumor-specific mutations in cerebral spinal fluid (CSF) may become an alternative method. Full-Text PDF Open Archive